HLSE:HRTIS

Stock Analysis Report

Executive Summary

Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine.


Snowflake Analysis

Reasonable growth potential and slightly overvalued.

Share Price & News

How has Herantis Pharma Oyj's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HRTIS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.4%

HRTIS

-0.01%

FI Pharmaceuticals

-2.8%

FI Market


1 Year Return

43.4%

HRTIS

18.5%

FI Pharmaceuticals

9.6%

FI Market

Return vs Industry: HRTIS exceeded the Finnish Pharmaceuticals industry which returned 18.5% over the past year.

Return vs Market: HRTIS exceeded the Finnish Market which returned 9.6% over the past year.


Shareholder returns

HRTISIndustryMarket
7 Day3.4%-0.01%-2.8%
30 Day0%1.5%0.6%
90 Day9.4%9.7%8.1%
1 Year43.4%43.4%25.2%18.5%14.6%9.6%
3 Year117.1%117.1%40.0%24.2%32.1%16.3%
5 Year15.0%15.0%39.2%15.6%44.8%17.5%

Price Volatility Vs. Market

How volatile is Herantis Pharma Oyj's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Herantis Pharma Oyj undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HRTIS (€7.6) is trading below our estimate of fair value (€100.39)

Significantly Below Fair Value: HRTIS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HRTIS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: HRTIS is unprofitable, so we can't compare its PE Ratio to the Finnish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HRTIS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HRTIS is overvalued based on its PB Ratio (19.4x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Herantis Pharma Oyj forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

102.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRTIS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.1%).

Earnings vs Market: HRTIS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HRTIS's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if HRTIS's revenue is forecast to grow faster than the Finnish market.

High Growth Revenue: Insufficient data to determine if HRTIS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HRTIS's Return on Equity is forecast to be very high in 3 years time (72.8%).


Next Steps

Past Performance

How has Herantis Pharma Oyj performed over the past 5 years?

26.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HRTIS is currently unprofitable.

Growing Profit Margin: HRTIS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HRTIS is unprofitable, but has reduced losses over the past 5 years at a rate of 26.9% per year.

Accelerating Growth: Unable to compare HRTIS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HRTIS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-5%).


Return on Equity

High ROE: HRTIS has a negative Return on Equity (-241.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Herantis Pharma Oyj's financial position?


Financial Position Analysis

Short Term Liabilities: HRTIS's short term assets (€5.6M) exceed its short term liabilities (€1.0M).

Long Term Liabilities: HRTIS's short term assets (€5.6M) do not cover its long term liabilities (€6.5M).


Debt to Equity History and Analysis

Debt Level: HRTIS's debt to equity ratio (279.5%) is considered high.

Reducing Debt: HRTIS's debt to equity ratio has increased from 23.4% to 279.5% over the past 5 years.


Balance Sheet

Inventory Level: HRTIS has a low level of unsold assets or inventory.

Debt Coverage by Assets: HRTIS's debt is not covered by short term assets (assets are 0.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HRTIS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HRTIS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Herantis Pharma Oyj's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.1%markettop25%4.5%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate HRTIS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HRTIS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HRTIS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HRTIS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HRTIS's dividend in 3 years as they are not forecast to pay a notable one for the Finnish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure


CEO

Pekka Simula 0

6.3yrs

Tenure

Mr. Pekka Ilmari Simula, M.Sc. (Tech) has been Chief Executive Officer of Herantis Pharma Oyj since his joining in November 2013 and serves as its Managing Director. Mr. Simula served as the Chief Operatin ...


Leadership Team

NamePositionTenureCompensationOwnership
Pekka Simula
CEO & MD6.3yrsno data0.46% 237.4k
Antti Vuolanto
Chief Operating Officer2yrsno data0.016% 8.5k
Henri Huttunen
Chief Scientific Officer10yrsno data1.11% 570.2k
Jutta Poutanen
Chief Pharmaceutical Officer9.5yrsno datano data
Outi Lahdenperä
Chief Medical Ofcer0yrsno datano data

7.9yrs

Average Tenure

Experienced Management: HRTIS's management team is seasoned and experienced (7.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jonathan Kenneth Knowles
Chairman of Scientific Advisory Board0yrsno datano data
Aki Prihti
Director6.1yrsno datano data
Timo Veromaa
Director8.1yrsno data0.067% 34.6k
James Phillips
Director6.1yrsno data0.043% 22.4k
Frans Wuite
Director6.1yrsno data0.046% 23.7k
Pekka Allan Mattila
Chairman of the Board7.1yrsno data0.037% 19.2k
Mart Saarma
Member of Scientific Advisory Board0yrsno data2.38% 1.2m
Kari Alitalo
Member of Scientific Advisory Board0yrsno datano data
Seppo Kaakkola
Member of Scientific Advisory Board0yrsno datano data
Alan Whone
Member of Scientific Advisory Board0yrsno datano data

6.1yrs

Average Tenure

59yo

Average Age

Experienced Board: HRTIS's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.2%.


Top Shareholders

Company Information

Herantis Pharma Oyj's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Herantis Pharma Oyj
  • Ticker: HRTIS
  • Exchange: HLSE
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €51.438m
  • Shares outstanding: 6.68m
  • Website: https://www.herantis.com

Number of Employees


Location

  • Herantis Pharma Oyj
  • Bertel Jungin Aukio 1
  • Espoo
  • 2600
  • Finland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HRTISHLSE (OMX Nordic Exchange Helsinki)YesShare CapitalFIEURJun 2014
HRNTSOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2014
HRPM.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2014

Biography

Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson’s disease, as well as in preclinical stage for the treatment of amyotrophic lateral sclerosis; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer associated lymphedema. Herantis Pharma Oyj was founded in 2008 and is based in Espoo, Finland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/18 22:44
End of Day Share Price2020/02/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.